TScan Therapeutics Named a Top Place to Work by The Boston Globe for Three Consecutive Years
TScan Therapeutics (Nasdaq: TCRX) has been recognized as one of the Top Places to Work in Massachusetts by The Boston Globe for the third consecutive year. The recognition is based on an employee survey conducted by Energage, involving nearly 68,000 employees across 323 Massachusetts organizations. The survey evaluates various aspects including company direction, execution, management, work environment, compensation, and employee engagement.
The company, which focuses on developing TCR-engineered T cell therapies for cancer treatment, was evaluated among different workplace categories based on employee count. CEO Gavin MacBeath highlighted the company's commitment to advancing their clinical-stage pipeline for heme malignancies and solid tumors, while SVP of Human Resources Ann Hargraves emphasized the organization's growth and culture development over the past five years.
TScan Therapeutics (Nasdaq: TCRX) è stata riconosciuta come uno dei Top Places to Work in Massachusetts dal Boston Globe per il terzo anno consecutivo. Questo riconoscimento si basa su un sondaggio condotto da Energage, che ha coinvolto quasi 68.000 dipendenti di 323 organizzazioni del Massachusetts. Il sondaggio valuta vari aspetti, tra cui la direzione dell'azienda, l'esecuzione, la gestione, l'ambiente di lavoro, la retribuzione e il coinvolgimento dei dipendenti.
L'azienda, che si concentra sullo sviluppo di terapie con cellule T ingegnerizzate TCR per il trattamento dei tumori, è stata valutata tra diverse categorie di luoghi di lavoro in base al numero di dipendenti. Il CEO Gavin MacBeath ha evidenziato l'impegno dell'azienda nel promuovere il proprio pipeline clinico per le neoplasie ematiche e i tumori solidi, mentre il SVP delle Risorse Umane Ann Hargraves ha sottolineato la crescita dell'organizzazione e lo sviluppo della cultura negli ultimi cinque anni.
TScan Therapeutics (Nasdaq: TCRX) ha sido reconocida como uno de los Mejores Lugares para Trabajar en Massachusetts por The Boston Globe por tercer año consecutivo. Este reconocimiento se basa en una encuesta a empleados realizada por Energage, que involucra casi 68,000 empleados de 323 organizaciones en Massachusetts. La encuesta evalúa varios aspectos, incluyendo la dirección de la empresa, la ejecución, la gestión, el ambiente laboral, la compensación y el compromiso de los empleados.
La empresa, que se enfoca en el desarrollo de terapias con células T ingenierizadas TCR para el tratamiento del cáncer, fue evaluada en diferentes categorías de lugares de trabajo según la cantidad de empleados. El CEO Gavin MacBeath destacó el compromiso de la empresa con el avance de su pipeline clínico para las malignidades hematológicas y los tumores sólidos, mientras que la SVP de Recursos Humanos Ann Hargraves enfatizó el crecimiento de la organización y el desarrollo cultural en los últimos cinco años.
TScan Therapeutics (Nasdaq: TCRX)는 보스턴 글로브에 의해 매사추세츠에서 일하기 좋은 장소 TOP 중 하나로 세 번째 연속 인정을 받았습니다. 이 인정은 Energage가 실시한 직원 설문조사를 기반으로 하며, 323개의 매사추세츠 조직에 걸쳐 거의 68,000명의 직원이 참여했습니다. 설문조사는 회사의 방향, 실행, 관리, 근무 환경, 보상 및 직원 참여와 같은 다양한 측면을 평가합니다.
癌 치료를 위한 TCR-조작 세포 요법 개발에 집중하는 이 회사는 직원 수에 따라 다양한 직장 범주에서 평가되었습니다. CEO Gavin MacBeath는 혈액 악성 종양과 고형 종양을 위한 임상 단계 파이프라인의 발전에 대한 회사의 헌신을 강조했으며, 인사 부사장 Ann Hargraves는 지난 5년 동안 조직의 성장 및 문화 개발을 강조했습니다.
TScan Therapeutics (Nasdaq: TCRX) a été reconnu comme l'un des meilleurs lieux de travail dans le Massachusetts par le Boston Globe pour la troisième année consécutive. Cette reconnaissance repose sur une enquête auprès des employés réalisée par Energage, impliquant près de 68 000 employés de 323 organisations du Massachusetts. L'enquête évalue divers aspects tels que la direction de l'entreprise, l'exécution, la gestion, l'environnement de travail, la rémunération et l'engagement des employés.
L'entreprise, qui se concentre sur le développement de thérapies cellulaires T à ingénierie TCR pour le traitement du cancer, a été évaluée parmi différentes catégories de lieux de travail en fonction du nombre d'employés. Le PDG Gavin MacBeath a souligné l'engagement de l'entreprise à faire progresser son pipeline clinique pour les maladies hématologiques et les tumeurs solides, tandis que la SVP des ressources humaines Ann Hargraves a accentué la croissance de l'organisation et le développement de la culture au cours des cinq dernières années.
TScan Therapeutics (Nasdaq: TCRX) wurde zum dritten Mal in Folge von der Boston Globe als einer der Top-Arbeitgeber in Massachusetts ausgezeichnet. Diese Auszeichnung basiert auf einer Mitarbeiterumfrage, die von Energage durchgeführt wurde und fast 68.000 Mitarbeiter aus 323 Organisationen in Massachusetts einbezog. Die Umfrage bewertet verschiedene Aspekte wie Unternehmensführung, Umsetzung, Management, Arbeitsumfeld, Vergütung und Mitarbeiterengagement.
Das Unternehmen, das sich auf die Entwicklung von TKR-engineerten T-Zelltherapien zur Krebsbehandlung konzentriert, wurde in verschiedenen Arbeitsplatzkategorien je nach Mitarbeiterzahl bewertet. CEO Gavin MacBeath hob das Engagement des Unternehmens für den Fortschritt seiner klinischen Pipeline bei hämatologischen Malignitäten und soliden Tumoren hervor, während die SVP für Personalwesen, Ann Hargraves, das Wachstum der Organisation und die Entwicklung der Unternehmenskultur in den letzten fünf Jahren betonte.
- None.
- None.
WALTHAM, Mass., Dec. 05, 2024 (GLOBE NEWSWIRE) -- TScan Therapeutics, Inc. (Nasdaq: TCRX), a clinical-stage biotechnology company focused on the development of T cell receptor (TCR)-engineered T cell (TCR-T) therapies for the treatment of patients with cancer, today announced it has been named one of the Top Places to Work in Massachusetts in the 17th annual, employee-based survey from The Boston Globe. The 2024 Top Places to Work issue was published online at Globe.com/TopPlaces and will appear in Globe Magazine on Sunday, December 8, 2024.
Top Places to Work recognizes the most admired workplaces in the state voted on by the people who know them best – their employees. The survey measures employee opinions about their company’s direction, execution, connection, management, work, pay, benefits, and engagement. The employers are placed into one of four groups: small, with 50 to 99 employees; medium, with 100 to 249 workers; large, with 250 to 999; and largest, with 1,000 or more.
“At TScan we are committed to advancing our clinical-stage pipeline across heme malignancies and solid tumors to deliver novel treatment options for patients with different types of cancer,” said Gavin MacBeath, Ph.D., Chief Executive Officer. “I am truly thankful for the hard work and passion of our mission-driven team, whose continuous dedication to improving the lives of patients living with cancer creates an exceptional workplace culture.”
“This is the third consecutive year that TScan has been recognized as a Top Place to Work, an achievement that reflects the dedication, inclusivity, and employee-centric values that define our organization,” added Ann Hargraves, Senior Vice President of Human Resources. “The progress that we have made as an organization in just five years is a direct result of the committed and unified team we have built and the incredible culture we have cultivated.”
The rankings in Top Places to Work are based on confidential survey information collected by Energage (formerly WorkplaceDynamics), an independent company specializing in employee engagement and retention, from nearly 68,000 employees at 323 Massachusetts organizations. The winners are constantly working to improve their workplaces and help employees get to know each other in an increasingly hybrid environment.
Top Places to Work online extras include sortable rankings and features that showcase companies that are dedicated to meeting the evolving needs of its employees. All information is available at Globe.com/TopPlaces. Follow the news on social media using the hashtag #workboston.
About TScan Therapeutics, Inc.
TScan is a clinical-stage biotechnology company focused on the development of T cell receptor (TCR)-engineered T cell (TCR-T) therapies for the treatment of patients with cancer. The Company’s lead TCR-T therapy candidates are in development for the treatment of patients with hematologic malignancies to prevent relapse following allogeneic hematopoietic cell transplantation (the ALLOHATM Phase 1 heme trial). The Company has developed and continues to expand its ImmunoBank, the Company’s repository of therapeutic TCRs that recognize diverse targets and are associated with multiple HLA types, to provide customized multiplex TCR-T therapies for patients with a variety of cancers (the PLEXI-TTM Phase 1 solid tumor trial). The Company is currently enrolling patients into both clinical programs.
About Boston Globe Media
Boston Globe Media Partners, LLC is a locally owned, award-winning media company serving Boston and New England. The cornerstone of the brand is The Boston Globe, a 27-time Pulitzer Prize-winning news source and one of the most successful metro news organizations in the United States. The Globe is headquartered in Boston with regional bureaus in Washington, D.C., Rhode Island, and New Hampshire. The Globe has one of the highest daily print circulations among metro newspapers and more than 245,000 digital subscribers. As part of Boston Globe Media's growing portfolio of brands, the Globe hosts events that connect community members to its journalism and provides a range of digital and home-delivered advertising solutions that reach more consumers than any other New England media brand. Boston Globe Media's properties include The Boston Globe, Globe.com, Boston.com, STAT, The B-Side, Globe Publishing Services, Globe Events, Studio/B, and the weekday news program Boston Globe Today on NESN and online.
Contacts
Heather Savelle
TScan Therapeutics, Inc.
VP, Investor Relations
857-399-9840
hsavelle@tscan.com
Maghan Meyers
Argot Partners
212-600-1902
TScan@argotpartners.com
FAQ
What recognition did TScan Therapeutics (TCRX) receive from The Boston Globe in 2024?
How many organizations and employees participated in The Boston Globe's 2024 workplace survey that included TCRX?
What is TScan Therapeutics' (TCRX) main business focus?
